Impaired immune and acute-phase responses in interleukin-6-deficient mice - PubMed (original) (raw)
. 1994 Mar 24;368(6469):339-42.
doi: 10.1038/368339a0.
Affiliations
- PMID: 8127368
- DOI: 10.1038/368339a0
Impaired immune and acute-phase responses in interleukin-6-deficient mice
M Kopf et al. Nature. 1994.
Abstract
Interleukin-6 (IL-6) is a multifunctional cytokine that regulates various aspects of the immune response, acute-phase reaction and haematopoiesis (for reviews see refs 1, 2). In vitro, leukaemia inhibitory factor, oncostatin M, ciliary neurotrophic factor and interleukin-11 display overlapping activities with IL-6. This functional redundancy may be explained by the interactions of specific binding receptors with a common signal-transducing receptor (gp130) (for reviews see refs 3, 4). To elucidate the unique function of IL-6 in vivo, we have disrupted the IL-6 gene by homologous recombination. IL-6-deficient mice develop normally. They fail to control efficiently vaccinia virus and infection with Listeria monocytogenes, a facultative intracellular bacterium. The T-cell-dependent antibody response against vesicular stomatitis virus is impaired. Further, the inflammatory acute-phase response after tissue damage or infection is severely compromised, whereas it is only moderately affected after challenge with lipopolysaccharide. We conclude that IL-6 production induced by injury or infection is an important in vivo SOS signal which coordinates activities of liver cells, macrophages and lymphocytes.
Similar articles
- IL-12 is not required for induction of type 1 cytokine responses in viral infections.
Oxenius A, Karrer U, Zinkernagel RM, Hengartner H. Oxenius A, et al. J Immunol. 1999 Jan 15;162(2):965-73. J Immunol. 1999. PMID: 9916721 - Expression of lymphotoxin beta governs immunity at two distinct levels.
Junt T, Tumanov AV, Harris N, Heikenwalder M, Zeller N, Kuprash DV, Aguzzi A, Ludewig B, Nedospasov SA, Zinkernagel RM. Junt T, et al. Eur J Immunol. 2006 Aug;36(8):2061-75. doi: 10.1002/eji.200626255. Eur J Immunol. 2006. PMID: 16841297 - Effector T-cell differentiation during viral and bacterial infections: Role of direct IL-12 signals for cell fate decision of CD8(+) T cells.
Keppler SJ, Theil K, Vucikuja S, Aichele P. Keppler SJ, et al. Eur J Immunol. 2009 Jul;39(7):1774-83. doi: 10.1002/eji.200839093. Eur J Immunol. 2009. PMID: 19548244 - [Interleukin-6].
Nishimoto N, Ogata A, Shima Y, Yoshizaki K. Nishimoto N, et al. Gan To Kagaku Ryoho. 1994 Aug;21(10):1707-16. Gan To Kagaku Ryoho. 1994. PMID: 8060152 Review. Japanese. - Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response.
Le JM, Vilcek J. Le JM, et al. Lab Invest. 1989 Dec;61(6):588-602. Lab Invest. 1989. PMID: 2481148 Review. No abstract available.
Cited by
- Toxoplasma gondii ROP5 Enhances Type I IFN Responses by Promoting Ubiquitination of STING.
Jin QW, Yu T, Pan M, Fan YM, Ge CC, He XB, Gong JZ, Tao JP, Fu BQ, Jing ZZ, Huang SY. Jin QW, et al. Int J Mol Sci. 2024 Oct 19;25(20):11262. doi: 10.3390/ijms252011262. Int J Mol Sci. 2024. PMID: 39457045 Free PMC article. - Interleukin 6 and cancer resistance in glioblastoma multiforme.
Detchou D, Barrie U. Detchou D, et al. Neurosurg Rev. 2024 Sep 5;47(1):541. doi: 10.1007/s10143-024-02783-5. Neurosurg Rev. 2024. PMID: 39231832 Review. - Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines.
Huber A, Allam AH, Dijkstra C, Thiem S, Huynh J, Poh AR, Konecnik J, Jacob SP, Busuttil R, Liao Y, Chisanga D, Shi W, Alorro MG, Forrow S, Tauriello DVF, Batlle E, Boussioutas A, Williams DS, Buchert M, Ernst M, Eissmann MF. Huber A, et al. Cell Rep. 2024 Aug 27;43(8):114616. doi: 10.1016/j.celrep.2024.114616. Epub 2024 Aug 9. Cell Rep. 2024. PMID: 39128004 Free PMC article. - PTEN acts as a crucial inflammatory checkpoint controlling TLR9/IL-6 axis in B cells.
Tsai PJ, Chen MY, Hsu WC, Lin SF, Chan PC, Chen HH, Kao CY, Lin WJ, Chuang TH, Yu GY, Su YW. Tsai PJ, et al. iScience. 2024 Jun 26;27(7):110388. doi: 10.1016/j.isci.2024.110388. eCollection 2024 Jul 19. iScience. 2024. PMID: 39092178 Free PMC article. - Intratumoral Delivery of Genetically Engineered Anti-IL-6 Trans-signaling Therapeutics.
Bento R, Scheller J, Parekkadan B. Bento R, et al. Mol Biotechnol. 2024 Jul 9. doi: 10.1007/s12033-024-01230-6. Online ahead of print. Mol Biotechnol. 2024. PMID: 38980514
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases